SPRY ARS Pharmaceuticals Inc
Price (delayed)
$13.05
Market cap
$1.28B
P/E Ratio
163.13
Dividend/share
N/A
EPS
$0.08
Enterprise value
$1.3B
Silverback Therapeutics, Inc. operates as a biotechnology company. The Company discovers and develops novel and proprietary ImmunoTAC technology, which is designed to create potent therapeutic molecules that can be systemically
Highlights
SPRY's EPS has surged by 116% since the previous quarter and by 114% year-on-year
The net income has soared by 116% QoQ and by 115% YoY
ARS Pharmaceuticals's quick ratio has plunged by 86% YoY but it has increased by 11% from the previous quarter
Key stats
What are the main financial stats of SPRY
Market
Valuations
Earnings
Shares outstanding
98.12M
Market cap
$1.28B
Enterprise value
$1.3B
Price to earnings (P/E)
163.13
Price to book (P/B)
4.94
Price to sales (P/S)
14.19
EV/EBIT
156.78
EV/EBITDA
155.3
EV/Sales
14.57
Revenue
$89.15M
Gross profit
$88.17M
Operating income
-$3.08M
Net income
$8M
EBIT
$8.29M
EBITDA
$8.37M
Free cash flow
$12.99M
Per share
Balance sheet
Liquidity
EPS
$0.08
EPS diluted
$0.08
Free cash flow per share
$0.13
Book value per share
$2.64
Revenue per share
$0.92
TBVPS
$3.55
Total assets
$351.15M
Total liabilities
$94.36M
Debt
$69.43M
Equity
$256.8M
Working capital
$310.86M
Debt to equity
0.27
Current ratio
14.26
Quick ratio
13.75
Net debt/EBITDA
2.22
Margins
Efficiency
Dividend
EBITDA margin
9.4%
Gross margin
98.9%
Net margin
9%
Operating margin
-3.5%
Return on assets
3.1%
Return on equity
3.6%
Return on invested capital
3.9%
Return on capital employed
2.5%
Return on sales
9.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SPRY stock price
How has the ARS Pharmaceuticals stock price performed over time
Intraday
4.15%
1 week
3.57%
1 month
24.52%
1 year
40.63%
YTD
23.7%
QTD
3.74%
Financial performance
How have ARS Pharmaceuticals's revenue and profit performed over time
Revenue
$89.15M
Gross profit
$88.17M
Operating income
-$3.08M
Net income
$8M
Gross margin
98.9%
Net margin
9%
The net income has soared by 116% QoQ and by 115% YoY
ARS Pharmaceuticals's net margin has soared by 100% from the previous quarter and by 100% YoY
ARS Pharmaceuticals's operating margin has surged by 100% YoY and by 100% QoQ
The company's operating income has surged by 95% YoY and by 95% QoQ
Growth
What is ARS Pharmaceuticals's growth rate over time
Valuation
What is ARS Pharmaceuticals stock price valuation
P/E
163.13
P/B
4.94
P/S
14.19
EV/EBIT
156.78
EV/EBITDA
155.3
EV/Sales
14.57
SPRY's EPS has surged by 116% since the previous quarter and by 114% year-on-year
The price to book (P/B) is 76% higher than the 5-year quarterly average of 2.7
ARS Pharmaceuticals's equity has increased by 28% from the previous quarter and by 11% YoY
The price to sales (P/S) is 100% lower than the last 4 quarters average of 25204.1
Efficiency
How efficient is ARS Pharmaceuticals business performance
SPRY's ROE has soared by 116% YoY and by 116% from the previous quarter
The company's return on assets has surged by 114% YoY and by 114% QoQ
SPRY's return on invested capital has surged by 113% since the previous quarter and by 112% year-on-year
SPRY's return on sales has surged by 100% since the previous quarter and by 100% year-on-year
Dividends
What is SPRY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SPRY.
Financial health
How did ARS Pharmaceuticals financials performed over time
ARS Pharmaceuticals's quick ratio has plunged by 86% YoY but it has increased by 11% from the previous quarter
The company's current ratio has shrunk by 85% YoY but it rose by 14% QoQ
ARS Pharmaceuticals's debt is 73% less than its equity
ARS Pharmaceuticals's equity has increased by 28% from the previous quarter and by 11% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.